Author

Xiao-Li Xiong

h-index 8 View on Semantic Scholar

We have 3 of 32 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

R1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation.

R1-32-like public antibodies, characterized by shared IGHV1-69/IGLV1-40 usage, are elicited in more than 50% of individuals with COVID-19 and have been implicated in driving recurrent mutations at L452SARS2 and F490SARS2 within their convergent epitope in the SARS-CoV-2 spike receptor-binding domain. These mutations ef...

Chuan-Ying Niu, Xiao-Han Huang, Qi-Hong Yan et al. · PLoS Biology · 0 citations

Open access Aug 2026

The S1B-Targeting PEDV Neutralizing Antibody C62 Prematurely Activates S-trimer and Mimics Receptor Function

The structure of PEDV HNXX-strain spike domain B (S1B) is determined and a strain-specific vulnerable site on the PEDV S-trimer is identified, providing insight into how cell-surface membrane fusion activity may influence viral entry pathway selection and antibody neutralization efficacy.

Jian-Bo Liu, Sheng Wang, Zi-Mu Li et al. · bioRxiv · 0 citations

Jul 2026

Targeted Degradation of Capsid by Host-Hijacking PROTAC Overcomes Drug Resistance.

This work pioneers the development of CA-targeted degraders, providing a framework for next-generation anti-HIV therapies with high potency and resistance barriers, via a proteasome-driven pathway.

Mei Wang, Ze-Yu Peng, Yang Zhou et al. · Journal of Medicinal Chemist... · 0 citations